FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167301388> ?p ?o ?g. }

• W3167301388 endingPage "8022" @default.
• W3167301388 startingPage "8022" @default.
• W3167301388 abstract "8022 Background: Maintenance therapy in multiple myeloma (MM) after first autologous hematopoietic cell transplantation (AHCT1) is considered standard of care. Data regarding maintenance therapy after a salvage AHCT (AHCT2) in the setting of relapsed MM are scarce. Therefore, we used data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry to examine the use of maintenance therapy after AHCT2 in MM patients and its effect on post-transplant patient outcomes. Methods: We included US adult MM patients who underwent AHCT2 after melphalan conditioning regimen from 2010-2018, and excluded patients who underwent tandem transplants. Outcomes of interest included non-relapse mortality (NRM), relapse/progression (REL), progression-free and overall survival (PFS, OS). Cox proportional hazards models were developed to study the main effect (maintenance use) with other covariates of interest including age, sex, race, performance status, HCT-comorbidity index, MM subtype, stage, creatinine, cytogenetic, conditioning melphalan dose, disease status at transplant, and time from AHCT1 to AHCT2. Results: Of 522 patients, 342 received maintenance therapy and 180 did not after AHCT2. Baseline characteristics were similar between the two groups. Median follow up was 58 months in the maintenance group and 61.5 months in the no-maintenance group. Common maintenance regimens included immunomodulatory drugs (IMID)-lenalidomide (N = 145, 42%) or pomalidomide (N = 46, 13%) and proteasome inhibitor, bortezomib (N = 45, 13%). Univariate analysis showed superior outcomes at 5 years in maintenance compared to the no-maintenance group: NRM 2 (0.7-3.9)% vs 9.9 (5.9-14.9)%, p < 0.001, REL 70.2 (64.4-75.8)% vs 80.3 (73.6-86.3)%, p 0.003, PFS 27.8% (22.4-33.5) vs. 9.8% (5.5-15.2), p < 0.001, and OS 54% (47.5-60.5) vs 30.9% (23.2-39.2) p < 0.001, respectively. IMID-containing maintenance regimens were associated with an improved 5-year PFS and OS compared to other maintenance regimens. Use of maintenance therapy retained its association with improved outcomes in multivariate analysis, including NRM: hazard ratio (HR) 0.19 (0.08-0.44), p 0.0001, REL: HR 0.58 (0.47-0.72), p < 0.0001, PFS HR 0.52 (0.43-0.64), p < 0.0001, and OS HR 0.46 (0.36-0.60), p < 0.0001. We conducted additional analyses to investigate a possible selection bias in the maintenance group including landmark analysis at 100-days and 6-months post-AHCT2 as well as a subgroup analysis of patients who received melphalan 200mg/m 2 as conditioning for AHCT2 (as a surrogate for fitness)- all these analyses also showed improved outcomes in the maintenance group. Second cancers were reported in 17 (5%) patients in the maintenance group and 6 (3%) patients and no-maintenance group (p 0.39). Conclusions: Maintenance therapy after AHCT2 is associated with superior outcomes in MM patients." @default.
• W3167301388 created "2021-06-22" @default.
• W3167301388 creator A5015342719 @default.
• W3167301388 creator A5023475751 @default.
• W3167301388 creator A5026574827 @default.
• W3167301388 creator A5027540829 @default.
• W3167301388 creator A5036605555 @default.
• W3167301388 creator A5050422684 @default.
• W3167301388 creator A5053904944 @default.
• W3167301388 creator A5071516639 @default.
• W3167301388 creator A5083122598 @default.
• W3167301388 creator A5085701502 @default.
• W3167301388 date "2021-05-20" @default.
• W3167301388 modified "2023-09-26" @default.
• W3167301388 title "Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study." @default.
• W3167301388 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.8022" @default.
• W3167301388 hasPublicationYear "2021" @default.
• W3167301388 type Work @default.
• W3167301388 sameAs 3167301388 @default.
• W3167301388 citedByCount "1" @default.
• W3167301388 countsByYear W31673013882022 @default.
• W3167301388 crossrefType "journal-article" @default.
• W3167301388 hasAuthorship W3167301388A5015342719 @default.
• W3167301388 hasAuthorship W3167301388A5023475751 @default.
• W3167301388 hasAuthorship W3167301388A5026574827 @default.
• W3167301388 hasAuthorship W3167301388A5027540829 @default.
• W3167301388 hasAuthorship W3167301388A5036605555 @default.
• W3167301388 hasAuthorship W3167301388A5050422684 @default.
• W3167301388 hasAuthorship W3167301388A5053904944 @default.
• W3167301388 hasAuthorship W3167301388A5071516639 @default.
• W3167301388 hasAuthorship W3167301388A5083122598 @default.
• W3167301388 hasAuthorship W3167301388A5085701502 @default.
• W3167301388 hasConcept C126322002 @default.
• W3167301388 hasConcept C141071460 @default.
• W3167301388 hasConcept C143998085 @default.
• W3167301388 hasConcept C2776063141 @default.
• W3167301388 hasConcept C2776364478 @default.
• W3167301388 hasConcept C2776694085 @default.
• W3167301388 hasConcept C2777478702 @default.
• W3167301388 hasConcept C2778283404 @default.
• W3167301388 hasConcept C2778524551 @default.
• W3167301388 hasConcept C2778684742 @default.
• W3167301388 hasConcept C2780775027 @default.
• W3167301388 hasConcept C2911091166 @default.
• W3167301388 hasConcept C71924100 @default.
• W3167301388 hasConceptScore W3167301388C126322002 @default.
• W3167301388 hasConceptScore W3167301388C141071460 @default.
• W3167301388 hasConceptScore W3167301388C143998085 @default.
• W3167301388 hasConceptScore W3167301388C2776063141 @default.
• W3167301388 hasConceptScore W3167301388C2776364478 @default.
• W3167301388 hasConceptScore W3167301388C2776694085 @default.
• W3167301388 hasConceptScore W3167301388C2777478702 @default.
• W3167301388 hasConceptScore W3167301388C2778283404 @default.
• W3167301388 hasConceptScore W3167301388C2778524551 @default.
• W3167301388 hasConceptScore W3167301388C2778684742 @default.
• W3167301388 hasConceptScore W3167301388C2780775027 @default.
• W3167301388 hasConceptScore W3167301388C2911091166 @default.
• W3167301388 hasConceptScore W3167301388C71924100 @default.
• W3167301388 hasFunder F4320332161 @default.
• W3167301388 hasIssue "15_suppl" @default.
• W3167301388 hasLocation W31673013881 @default.
• W3167301388 hasOpenAccess W3167301388 @default.
• W3167301388 hasPrimaryLocation W31673013881 @default.
• W3167301388 hasRelatedWork W1851688703 @default.
• W3167301388 hasRelatedWork W2050991415 @default.
• W3167301388 hasRelatedWork W2056322049 @default.
• W3167301388 hasRelatedWork W2080302923 @default.
• W3167301388 hasRelatedWork W2143221570 @default.
• W3167301388 hasRelatedWork W2143956697 @default.
• W3167301388 hasRelatedWork W2988985062 @default.
• W3167301388 hasRelatedWork W3030546096 @default.
• W3167301388 hasRelatedWork W3167301388 @default.
• W3167301388 hasRelatedWork W4233590833 @default.
• W3167301388 hasVolume "39" @default.
• W3167301388 isParatext "false" @default.
• W3167301388 isRetracted "false" @default.
• W3167301388 magId "3167301388" @default.
• W3167301388 workType "article" @default.